glp-1 news october 16 2025 Consumers' Expectations about Drugs Economic Impact on Food System Players GLP-1 Trends: Access & Shortages,

Description

Liraglutide (LEADER trial), semaglutide (SUSTAIN-6), and dulaglutide (REWIND trial) have shown significant reductions in major adverse cardiovascular events (MACE) in patients with established cardiovascular disease or multiple cardiovascular risk factors

This kinase facilitates a series of downstream intracellular activities, culminating in enhanced insulin secretion from pancreatic beta cells

The further synergistic combination approach with other gastrointestinal hormones and creation of dual GIP/GLP-1 receptor agonists, such as tirzepatide and GLP-1/GIP/glucagon receptor triagonist, retatrutide, has shown unprecedented pharmacologically achieved weight loss with further cardiometabolic benefits in both obesity and T2DM

Additionally, some GLP-1s are approved for weight management in adults who meet BMI criteria with or without another metabolic dysfunction (like high blood pressure, diabetes, or high cholesterol)